Fig. 8. Schematic diagram showing the mechanism of intramuscularly-injected empagliflozin in enhancing therapeutic angiogenesis.
Empagliflozin inhibits hyperglycemia-induced ferroptosis in skeletal muscle cells by enhancing GPX4 expression, thus promoting revascularization in diabetic HLI mice.